Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic and endocrine disorders. Company press releases highlight progress across a pipeline that includes VK2735 for obesity and related metabolic conditions, VK2809 for lipid and liver disorders such as NASH and NAFLD, VK0214 for X-linked adrenoleukodystrophy (X-ALD), and an emerging program of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other metabolic diseases.
For VK2735, Viking regularly issues news on clinical milestones in both subcutaneous and oral tablet formulations. Recent announcements describe positive Phase 2 VENTURE trial results in obesity, with statistically significant weight loss and encouraging safety and tolerability, as well as Phase 2 VENTURE-Oral Dosing data showing meaningful weight reduction after 13 weeks of once-daily oral therapy. Additional releases cover the initiation and progress of the Phase 3 VANQUISH-1 and VANQUISH-2 trials, which evaluate weekly subcutaneous VK2735 in adults with obesity or overweight, including those with type 2 diabetes, over 78 weeks.
News items also detail exploratory maintenance dosing studies of VK2735 that examine monthly subcutaneous, weekly oral, and daily oral regimens following initial weight loss. Beyond obesity, Viking’s updates discuss VK2809’s Phase 2b success in biopsy-confirmed NASH and fibrosis, as well as Phase 2a results in NAFLD with elevated LDL-C, and VK0214’s Phase 1b data in X-ALD showing reductions in very long-chain fatty acids. Investors following VKTX news can expect coverage of clinical data presentations at scientific meetings, participation in healthcare and investor conferences, and SEC-reported corporate updates on financial results and pipeline status.
Viking Therapeutics (NASDAQ: VKTX) will release its Q1 2022 financial results on April 27, 2022, post-market. A conference call is scheduled for 4:30 PM ET the same day to discuss the results and corporate updates. Key clinical programs include VK2809, a treatment for NASH, and VK0214, investigating X-ALD. The company aims to leverage its expertise in metabolic therapies to enhance patient outcomes.
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian will present at the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022. Lian's presentation is scheduled for April 13, 2022, from 11:15 to 11:55 a.m. Pacific. Attendees can access a live webcast through the Viking Therapeutics website, which will also host a replay post-conference. Viking focuses on innovative therapies for metabolic and endocrine disorders, with ongoing clinical programs for its candidates VK2809, VK0214, and VK2735.
Viking Therapeutics (NASDAQ: VKTX) announced their participation in two investor conferences: the 34th Annual Roth Conference from March 13-15, 2022, and the Oppenheimer 32nd Annual Healthcare Conference from March 15-17, 2022. CEO Brian Lian will engage in a fireside chat and management will hold one-on-one meetings at Roth. At Oppenheimer, Lian will present on March 16 at 11:40 a.m. Pacific. The Oppenheimer presentation will be available via webcast. Viking focuses on developing therapies for metabolic disorders, including VK2809 for NASH and fibrosis.
Viking Therapeutics (NASDAQ: VKTX) announced its Q4 and full-year 2021 financial results, reporting a net loss of $12.4 million, or $0.16 per share, and a total net loss of $55.0 million, or $0.71 per share, for the year. The company continues its Phase 2b VOYAGE trial for VK2809, targeting NASH, while facing a clinical hold on the VK0214 trial for X-ALD pending additional studies. Viking maintains a strong cash position with over $200 million to support its clinical programs. New pipeline developments include VK2735, a dual GLP-1 and GIP receptor agonist.
Viking Therapeutics (NASDAQ: VKTX) announced its CEO, Brian Lian, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The chat is scheduled for February 16 at 2:00 PM Pacific. Attendees can access the live webcast via Viking's website in the Investors & Media section. Viking focuses on developing novel therapies for metabolic and endocrine disorders, including its lead candidate VK2809 for treating NASH.
Viking Therapeutics (NASDAQ: VKTX) will release its financial results for Q4 and year-end 2021 on February 9, 2022, after market close. The company will also host a conference call at 4:30 PM ET to discuss these results, along with general corporate updates. Investors can participate via phone or listen to the live webcast on Viking's website. Viking is focused on developing therapies for metabolic disorders, with candidates like VK2809, VK0214, and VK2735 in various stages of clinical trials.
Viking Therapeutics, Inc. (VKTX) announced a clinical hold by the FDA on its Phase 1b trial of VK0214 for X-linked adrenoleukodystrophy (X-ALD). The FDA requires an additional preclinical study, specifically a rodent genotoxicity study, before the trial can continue. This hold is not based on any findings from prior studies. The company expects to submit the requested data in Q2 2022, aiming to resume dosing later this year. VK0214 has previously shown promising safety and efficacy results, including reductions in LDL cholesterol and triglycerides.
Viking Therapeutics (NASDAQ: VKTX) announced the initiation of a Phase 1 clinical trial for VK2735, a novel dual agonist targeting GLP-1 and GIP receptors, aimed at treating metabolic disorders. This double-blind, placebo-controlled study will assess safety, tolerability, and pharmacokinetics in healthy adults, with exploratory assessments of body weight and liver fat changes. VK2735 is expected to enhance therapeutic effects compared to existing treatments like semaglutide. The trial marks a significant milestone for Viking, which aims to report topline results later in the year.
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will present at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be available online once the conference begins, with a webcast accessible via Viking's website. Viking Therapeutics focuses on developing innovative therapies for metabolic and endocrine disorders, including its lead candidates VK2809 and VK0214, which are in advanced stages of clinical trials.
Viking Therapeutics (NASDAQ: VKTX) will present at the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. CEO Brian Lian, Ph.D., is scheduled to speak on November 16 from 4:00 to 4:30 p.m. Eastern. Interested parties can access the presentation via the company's website, with a replay available post-conference. Viking focuses on therapies for metabolic and endocrine disorders, including VK2809, currently in a Phase 2b study for non-alcoholic steatohepatitis.